Patrick Reichl
Toxicology Lead
Patrick Reichl is currently Toxicology Lead at Croma Pharma GmbH. He has a PhD in biology as well as a Master’s degree in toxicology. In his PhD thesis, he investigated novel therapeutic targets in hepatocellular carcinoma. Afterwards, he worked in the pharmaceutical industry as a Toxicological Risk Assessor for Baxter. In 2019, Patrick joined Croma Pharma, where he is responsible for biocompatibility and chemical characterization studies for implantable medical devices, toxicological risk assessment and establishment of non-clinical submission strategies. His areas of expertise also include in silico toxicology and genotoxicity assessment of devices, excipients, materials and impurities.
DAY 2: December 5th, 2024
SESSION: Chemical Characterization and Toxicological Risk Assessment of Genotoxic Impurities in Medical Devices
◆ Establishment of the Analytical Evaluation Threshold (AET) for an implantable, absorbable medical device.
◆ Conducting in silico assessments of potential genotoxic impurities.
◆ Addressing recent regulatory developments and navigating associated challenges.
DAY 2: December 1st, 2023
SESSION: Genotoxic impurities in medical devices
◆ Regulatory framework for GIs in Medical Devices.
◆ Recent developments (ISO 10993-17:2023).
◆ Case studies.
DAY 2: December 3rd, 2021
SESSION: Genotoxic impurities in medical devices
◆ Regulatory framework for GIS in Medical Devices.
◆ Recent developments.
◆ Case studies.
